
**Title:** “Official American Thoracic Society / Centers for Disease Control / Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis”

**Subject of Planned Report:** This document summarizes the evidence informing clinical practices for the treatment of persons who have or are at risk for drug-susceptible tuberculosis, and makes recommendations for their optimal clinical and public health management.

**Purpose of Planned Report:** The information in this document updates and replaces the 2003 recommendations “Centers for Disease Control and Prevention. Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003; 52(No. RR-11).”

**Type of Dissemination:** Influential Scientific Information (ISI)

**Timing of Review (including deferrals):** October 2015-January 2016

**Type of Peer Review (panel, individual or alternative procedure):** Individual

**Opportunities for the Public to Comment (how and when):** These guidelines were presented and discussed during the scheduled public access webinar of the DHHS Secretary’s Advisory Council for the Elimination of Tuberculosis on April 26, 2016, to allow for public comment on the guideline recommendations. The webinar was recorded (audio) to provide a complete and accurate record.

**Peer Reviewers Provided with Public comments before the Review:** No

**Anticipated Number of Reviewers:** 6

**Primary Disciplines or Expertise:** Epidemiology, immunology, public health control, prevention, care and treatment of tuberculosis in the United States and Western Europe.

**Reviewers Selected by (agency or designated outside organization):** American Thoracic Society

**Public Nominations Requested for Reviewers:** No

**Charge to Peer Reviewers:** Peer reviewers received a request from the American Thoracic Society to peer review the Official American Thoracic Society / Centers for Disease Control / Infectious Diseases Society of America Clinical Practice Guidelines on Treatment of Drug-Susceptible Tuberculosis. Reviewers were asked for feedback about the accuracy, comprehensiveness, practicality, and clarity of the document, as well as the usefulness of the recommendations. By American Thoracic Society policy, reviewers were instructed that they must decline to review if: 1. The reviewer has a personal or institutional "competing interest" that is relevant to the subject matter and/or to its authors (or spouse/life partner or dependent has such an interest), which may cause or be perceived as a conflict of interest affecting the review AND/OR 2. The reviewer has a current relationship with a tobacco entity or had such within the past 12 months.
Peer Reviewers:

1) Joseph Keane, M.D.
Professor in Respiratory Medicine; Director, Clinical TB Services, St. James’ Supraregional Centre
Director, TB Immunology Lab; Trinity College Dublin; Dublin, Ireland
Expertise: Immunology of tuberculosis infection.

2) Jerrold Ellner, M.D.
Professor of Medicine; Chief, Section of Infectious Diseases
Boston University School of Medicine; Boston, Massachusetts, U.S.A.
Expertise: Tuberculosis and its interactions with co-HIV infection.

3) Christopher C. Whalen, M.D., M.S.
Professor of Medicine; Department of Epidemiology and Biostatistics
University of Georgia College of Public Health; Athens, Georgia, U.S.A.
Expertise: Epidemiology of tuberculosis; tuberculosis and its interactions with HIV co-infection.

4) Joseph Burzynski, MD
Bureau of Tuberculosis Control; NYC Department of Health and Mental Hygiene
Long Island City, New York, U.S.A.
Expertise: Transmission and public health consequences of tuberculosis.

5) Max O’Donnell, MD, MPH
Assistant Professor; Division of Pulmonary, Allergy, and Critical Care
Department of Medicine; Department of Epidemiology
Columbia University Medical Center; New York, New York, U.S.A.
Expertise: Epidemiology of tuberculosis; transmission of tuberculosis, particularly multidrug-resistant tuberculosis and extreme drug-resistant tuberculosis; and, treatment outcomes of patients with extreme drug-resistant tuberculosis and HIV co-infection.

6) Rocio Hurtado, M.D., D.T.M. & H.
Assistant Professor of Medicine; Harvard Medical School
Director, Mycobacterial Center; Massachusetts General Hospital; Boston MA USA
Expertise: clinical management of tuberculosis including drug-resistant tuberculosis; extrapulmonary disease and HIV co-infection.